Microbial API Global Market Report 2024

The microbial API market size has grown strongly in recent years. It will grow from $58.19 billion in 2023 to $62.9 billion in 2024 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to the increased demand for drugs, a heightened focus of governments on healthcare and pharmaceuticals, a growing need to meet nutritional requirements, sustainability and cost-efficiency, and a rise in the demand for biological drugs.

The microbial API market size is expected to see strong growth in the next few years. It will grow to $86.22 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to the increasing applications in the pharmaceutical industry, the rising prevalence of chronic conditions, higher healthcare expenditures, improved access to advanced medical infrastructure, and the growing incidence of infections and antibiotic resistance. Major trends expected during the forecast period include advancements in fermentation and downstream processing technologies, innovations in microbial fermentation technologies, increased investments in bioprocessing, advancements in molecular biology and synthetic biology, and product innovation.

The increasing prevalence of chronic conditions is expected to drive the growth of the microbial API market. Chronic conditions, which are long-lasting health issues or diseases, are becoming more common due to various factors such as aging populations, sedentary lifestyles, poor diets, environmental changes, and improved detection and diagnosis of diseases. Microbial APIs are increasingly utilized in managing chronic conditions, leveraging therapeutic properties derived from microorganisms to develop effective treatments. For instance, according to the International Diabetes Federation (IDF), a Belgium-based diabetes organization, the global number of people with diabetes was predicted to reach 537 million in 2.02 trillion by 2030, and 783 million by 2045, with an estimated 541 million people having impaired glucose tolerance by 2021. Additionally, nearly 6.7 million individuals aged 20 to 79 were expected to die from diabetes-related complications in 2021. Therefore, the rising prevalence of chronic conditions is propelling the growth of the microbial API market.

Leading companies in the microbial API market are developing novel API products, such as excipients, to enhance drug efficacy, improve formulation stability, and meet regulatory standards. Excipients are substances formulated alongside the active ingredient of medication to serve various purposes, including stabilization, bulking up formulations, enhancing therapeutic properties, and aiding in manufacturing. For instance, in October 2023, Clariant, a Switzerland-based chemical company, launched a new range of excipients to improve the stability and solubility of active pharmaceutical ingredients (APIs). This expansion includes three new VitiPure excipients designed to address challenges in API delivery and bioavailability, catering to various dosage applications such as oral, topical, and parenteral administration. These excipients aim to support the pharmaceutical industry by providing effective carrier systems for drug delivery, especially for sensitive medications such as mRNA vaccines and biologics.

In February 2022, Recipharm, a Sweden-based pharmaceutical contract development and manufacturing organization (CDMO), acquired Arranta Bio MA LLC for an undisclosed amount. This acquisition aims to enhance Recipharm's biologics manufacturing capabilities and establish a robust US platform for providing innovative drug developers with differentiated contract development and manufacturing services for advanced therapy medicinal products (ATMPs). Arranta Bio MA LLC is a US-based biotechnology company that provides microbial APIs.

Major companies operating in the microbial API market are BASF SE, Merck& Co Inc., AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca Plc, GlaxoSmithKline Plc, Eli Lilly And Company, Boehringer Ingelheim GmbH, Amgen Inc., Evonik Industries AG, TEVA Pharmaceutical industries Ltd., Lonza Group AG, Catalent Inc., CSPC Pharmaceutical Group Ltd., Patheon, Dr. Reddy's Laboratories Ltd., Siegfried Ltd., Recipharm AB, Shandong Lukang Pharmaceutical Co. Ltd., Tianjin Tianyao Pharmaceuticals Co. Ltd., Xellia Pharmaceuticals, Kolon Life Science Inc., Royal DSM NV, Henan Topfond Pharmaceutical Co. Ltd.

Asia-Pacific was the largest region in the microbial API market in 2023. The regions covered in the microbial api market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the microbial API market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Microbial APIs (active pharmaceutical ingredients) are pharmaceutical compounds produced through microbial fermentation processes. These compounds are created by cultivating microorganisms such as bacteria, fungi, or yeast, and then extracting the desired compound.

The main types of microbial APIs include antibodies, peptides, proteins, small molecules, and vaccines. An antibody is a protein produced by the immune system that binds to specific molecules called antigens. These APIs can be derived from different hosts, including mammalian, bacterial, and fungal sources, and can be produced in various sites, either in-house or outsourced. They encompass both innovative and generic molecules and are utilized by several end-users, including pharmaceutical and biopharmaceutical companies, among others.

The microbial API market research report is one of a series of new reports that provides microbial API market statistics, including microbial API industry global market size, regional shares, competitors with a microbial API market share, detailed microbial API market segments, market trends and opportunities, and any further data you may need to thrive in the microbial API industry. This microbial API market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The microbial API market consists of sales of, glycerin, and hydrolyzed yeast protein, salvia sclarea oil, allantoin and other related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.